Research, Charts & Company Announcements
Research Tree offers MESOBLAST LTD research coverage from 1 professional analysts, and we have 5 reports on our platform.
Our simple but effective charting function allows for a quick scan of MESOBLAST LTD's performance over multiple time horizons.
Frequency of research reports
Research reports on MESOBLAST LTD
Providers covering MESOBLAST LTD
Tightening focus to extend runway
21 Sep 16
Mesoblast cut its cash burn by 15% in FY16 to US$90m, and guided for a further ~25% reduction in FY17, which will give it headroom to fund the Phase III heart failure (HF) trial that Teva relinquished in June. It has ~12 months of cash runway plus a US$90m equity finance facility, which will give a further 12 months’ runway. It expects to report interim analyses of three Phase III programmes by end Q117, including the HF trial. We lower our valuation ahead of these potential catalysts to A$1.5bn from A$1.8bn (A$3.84 per share from A$4.67), due to lower forecast uptake in HF and removal of two low-priority tier two programmes.
Teva returns rights to cardiovascular programme
08 Jul 16
Teva has relinquished all rights to cardiovascular applications of Mesoblast’s mesenchymal precursor cell (MPC) technology, as it focuses on its core CNS and respiratory interests. Mesoblast will seek a new partner with a cardiovascular focus at the appropriate time. It has entered an A$120m (~US$90m) equity finance facility with Kentgrove Capital to fund the ongoing Phase III CHF trial and a 600-patient confirmatory trial (estimated cost ~US$90m), and has brought forward the interim futility analysis to Q117. We have revised our development timelines and lower our valuation to A$1.8bn from A$2.8bn (A$4.67 from A$7.36 per share).
Impressive signs of efficacy in rheumatoid arthritis
18 Feb 16
Mesoblast has reported impressive efficacy data from the first cohort of the Phase II trial of its mesenchymal precursor cell (MPC) product in rheumatoid arthritis (RA), ahead of full results due in Q316. Key catalysts next quarter will be the first interim analysis from the pivotal MPC-150-IM heart failure trial, together with an update to trial timelines following the halving of the trial to 600 patients. The launch of Temcell in Japan for graft vs host disease this quarter will bring a royalty stream from partner JCR Pharmaceuticals. We lift our valuation to A$7.36 per share (from A$7.20).
Headway on positive developments
23 Jul 15
Mesoblast is steadily advancing its pipeline, presenting positive Phase II data at the American Diabetes Association in June for MPC-300-IV in moderate-to-severe diabetic nephropathy. The company is seeking an accelerated regulatory path on findings in a large patient population with little alternative for treatment. The recent agreement with Celgene, which entailed a net A$58.5m equity purchase in return for first right of refusal on products in certain disease areas, provides Mesoblast with a capital injection and potential development/commercialisation partner. Meanwhile, an imminent regulatory decision in Japan for MSC-100-IV in acute graft vs host disease (aGvHD) could prove a significant share price catalyst. If approved, MSC-100-IV would be Mesoblast’s first product to market.
Research on related companies
View the latest research on other companies in the sector, published by expert analysts across the city, at some of the best quality Banks, Brokers, and Independent Providers in the market.
21 Oct 16
STM* (STM): Acquisition of London & Colonial (CORP) | Hurricane Energy (HUR): £70m placing and open offer (BUY) | Firestone Diamonds* (FDI): Liqhobong commissioning update (BUY) | Accsys (AXS): Acorn aiming to be a mighty oak – analyst interview (BUY) | Avacta* (AVCT): Act now… – analyst interview (CORP) | Tristel* (TSTL): Full year 2016 results – analyst interview (CORP)
Panmure Morning Note 27-10-2016
27 Oct 16
CareTech announces that trading to September 2016 is in line with market expectations. The company continues to trade at a significant discount to peers, we believe this is unjustified given the consistent performance in recent periods, including double digit EBITDA growth and high dividend yield. We maintain our BUY recommendation and 380p price target.
N+1 Singer - Morning Song 26-10-2016
26 Oct 16
Verona Pharma has been awarded its second Venture and Innovation Award from the UK Cystic Fibrosis Trust for the development of RPL554 in Cystic Fibrosis (CF). The award signals the significant potential for RPL554 to be developed as a novel treatment for Cystic Fibrosis. Preliminary data supports the molecule’s potential utility in this indication, demonstrating RPL554’S ability to activate an ion channel known to be dysfunctional in CF. The award will support a Phase IIa clinical trial expected to commence in H1 2017. Preparations have also started for Phase IIb trials of RPL554 as a nebulised treatment for COPD with clinical dosing expected to commence in Q2 2017. We remain extremely encouraged by the expanding opportunity of RPL554 and Verona Pharma’s future prospects.
25 Oct 16
"London’s blue chip index is called some 15 points higher during this morning’s opening trade, which should see the FTSE-100 test the psychologically important 7000 level once again. The US markets, whose principal indices all closed higher overnight, remain Europe’s main influence as investors track the territory’s latest round of deals and earnings. While broadly pleasing investors, technology issues continue to lead the way which resulted in the NASDAQ registering a full 1% rise on good trading volumes. Against this background, the Federal Reserve Bank of Chicago President, Charles Evans, delivered a speech in which he predicted three US interest-rate rises before the end of 2017, while effectively suggesting that the central bank should allow its inflation target to be overshot before responding with confidence strangling hikes. Generally, however, his forecasts are not far from the current consensus, although he refused to be drawn of the timing of the first move which the markets continue to anticipate in the form of a 25bp move being delivered before the 2016 year-end. By comparison, Asia ended mixed, with the Shanghai Composite finishing unchanged as a weaker Yuan was countered by gains in resource stocks; the latter also boosted the ASX’s commodity-heavy index while a weaker Yen resulted in the Nikkei closing the session with the region’s strongest gain. No major UK macro data are due for release today, which means that traders will eyes will remain focussed on the US disclosure of consumer confidence and housing figures due this afternoon, with neither the ECB President Mario Draghi’s scheduled lecture or the Bank of England Governor, Mark Carney’s appearance before the Lord’s Committee, expected to provide significant new market-sensitive information. Earnings or trading updates are expected from Anglo American Carpetright (AAL.L), GKN (GKN.L), National Express (NEX.L) and Whitbread (WTB.L). Significant quarterly earnings also due from US majors due this afternoon include Apple and General Motors. " - Barry Gibb, Research Analyst
FY 2016 results
17 Oct 16
Full-year results were 7% ahead of the August trading update. Revenue growth of 27% was driven by Vitamin D, up c55%, and sterling's depreciation, which contributed c11% to growth. A higher final dividend together with a 20p special dividend implies a combined yield of 2.9%. Management is confident that Siemens will launch its troponin-based assay contributing to and largely replacing lost NT proBNP royalties in FY 2018. We have increased our target price to 1450p to reflect a 5% EPS upgrade to 2017 earnings and introduced a 2018 forecast, calling for EPS of 72.7p.